Quantcast
Home > Quotes > NK
NK

NantKwest, Inc. Common Stock (NK) Quote & Summary Data

$2.36
*  
0.39
14.18%
Get NK Alerts
*Delayed - data as of Nov. 12, 2018  -  Find a broker to begin trading NK now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
4
Today's High / Low
$ 2.91 / $ 2.29
Share Volume
834,458
50 Day Avg. Daily Volume
566,821
Previous Close
$ 2.75
52 Week High / Low
$ 5.47 / $ 2.16
Market Cap
186,930,587
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.25
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.44

Intraday Chart

Shares Traded

Share Volume:
834,458
50 Day Avg. Daily Volume:
566,821

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.25

Trading Range

The current last sale of $2.36 is 9.26% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.91 $ 5.47
 Low: $ 2.29 $ 2.16

Company Description (as filed with the SEC)

We are a pioneering clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Natural killer, or NK, cells are the body's first line of defense due to their innate ability to rapidly seek and destroy abnormal cells, such as cancer or virally-infected cells, without prior exposure or activation by other support molecules required to activate adaptive immune cells such as T-cells. We believe that our proprietary NK cell line, coupled with our planned integrated discovery ecosystem, positions us to implement precision cancer medicine by leveraging the advances that have evolved during the past decade and addressing newly discovered challenges of cancer.  ... More ...  


Risk Grade

Where does NK fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.74
Open Date:
Nov. 12, 2018
Close Price:
$ 2.36
Close Date:
Nov. 12, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x